SIBO vs IBS: How to Tell the Difference (and Why It Matters)

Bloating, gas, cramping, unpredictable bowel habits. If you took a hundred people with these symptoms and asked a gastroenterologist what's going on, a lot of the answers would land in one of two buckets: irritable bowel syndrome (IBS) or small intestinal bacterial overgrowth (SIBO). They present the same. Patients get bounced between the diagnoses for years. The confusion is understandable, because the two conditions overlap heavily - one meta-analysis found SIBO in about 31% of IBS patients, roughly 3.7 times the rate in healthy controls (Shah et al., 2020).

But they're not the same condition, and the distinction matters. IBS is a disorder of how the gut and brain talk to each other. SIBO is a microbial problem in the wrong part of the intestine. One is treated with diet, gut-directed therapy, and neuromodulators. The other, often, with a two-week course of antibiotics. Getting the diagnosis right changes what treatment actually works.

The One-Line Difference

IBS is a wiring problem. SIBO is a plumbing problem.

IBS is what gastroenterologists now call a disorder of gut-brain interaction. The intestines look normal on scopes and imaging. Nothing is inflamed, obstructed, or infected. What's abnormal is the signaling: the gut is hypersensitive to normal stretch, motility is dysregulated, and the crosstalk between the enteric nervous system and the brain is off-kilter. The American College of Gastroenterology pegs IBS prevalence at 10-15% of adults globally. A 2023 nationwide US survey using Rome IV criteria - the strictest current standard - found 6.1% of Americans meet the definition (Almario et al., 2023).

SIBO is different. It's a biological event: too many bacteria, or the wrong kinds, colonizing a stretch of small intestine that's supposed to be relatively sparse. The Mayo Clinic defines it as either excessive numbers of bacteria or the wrong species relative to what belongs there. When those bacteria ferment carbs before your body absorbs them, they produce gas - hydrogen, methane, or hydrogen sulfide - and the gas is what drives most of the symptoms.

The two mechanisms are unrelated at a biological level. That they produce nearly identical symptoms is a coincidence of anatomy: the small intestine only has so many ways to complain.

Why the Overlap Is So Big

The confusion isn't just clinical impression. It's real. A 2020 meta-analysis pooling 25 case-control studies (3,192 IBS patients vs 3,320 controls) put SIBO prevalence in IBS at 31% with an odds ratio of 3.7 versus controls (Shah et al., 2020). Earlier work using lactulose breath testing specifically had put the number higher - some studies over 60%. The number floats with the diagnostic method, the population, and the SIBO cutoff being used, but the direction is consistent: SIBO is several times more common in people with IBS than in people without it.

Why? Two plausible reasons, and they might both be right:

• IBS creates a permissive environment for SIBO. The dysmotility that defines a lot of IBS - especially the constipation-predominant variety - slows the migrating motor complex, the housekeeping wave that sweeps bacteria toward the colon between meals. Bacteria that would normally get flushed downstream linger and multiply.
• SIBO looks so much like IBS that a chunk of "IBS" cases are actually SIBO. The Rome IV criteria for IBS explicitly assume no organic cause has been found. But most patients are diagnosed on symptoms alone, without a breath test to rule out SIBO. Some fraction of every IBS clinic is people whose bacterial overgrowth was never checked.

The overlap is largest in IBS with diarrhea (IBS-D) and in post-infectious IBS. Post-infectious IBS - the syndrome that follows a bout of bacterial gastroenteritis - pools at an 11% prevalence in exposed individuals, roughly 4.2 times the baseline rate (Klem et al., 2017). Anti-vinculin and anti-CdtB antibodies produced during the initial infection are thought to damage the migrating motor complex, setting up both the ongoing IBS and, in many patients, the SIBO that comes along with it.

Symptom Patterns That Actually Diverge

Symptoms alone won't cleanly separate SIBO from IBS in most patients. But there are patterns that lean one way or the other. If you're comparing your history against what your gastroenterologist is likely to ask about, these are the tells.

Leans SIBO

• Bloating that gets worse through the day. Flat stomach in the morning, visibly distended by evening. This tracks with meals feeding the overgrown bacteria and fermentation building through the day.
• Gas out of proportion to what you ate. Belching and flatulence that seem excessive for the meal, hitting fast after eating.
• Symptoms that clearly followed a trigger. A course of PPIs, abdominal surgery, an episode of gastroenteritis, starting an opioid. SIBO usually has a story behind it - it's rarely spontaneous.
• B12 deficiency, iron deficiency, or unintentional weight loss. Advanced SIBO consumes B12 and bile salts before you absorb them. The Merck Manual notes macrocytic anemia and steatorrhea in advanced cases.
• Fatty, foul, floating stools (steatorrhea). Fat malabsorption is a SIBO fingerprint, not an IBS one.
• Improvement with antibiotics. If a course of amoxicillin for something unrelated made your GI symptoms disappear for a while, that's a clue.

Leans IBS

• Pain relieved by defecation. This is one of the Rome IV criteria and one of the more consistent IBS signatures. SIBO pain is not as reliably tied to bowel movements.
• Symptoms tightly linked to stress or emotion. Anxiety flares, work pressure, life transitions. IBS lives at the gut-brain interface; SIBO doesn't.
• Long-standing history from adolescence or young adulthood. IBS typically shows up before age 50. Late-onset symptoms without an IBS history should raise a red flag for something else, SIBO included.
• Bowel habit changes that fit a clear subtype. Persistent constipation (IBS-C), persistent diarrhea (IBS-D), or clean alternation between them (IBS-M) - each with the stool form landing in a particular Bristol range (see our Bristol Stool Chart guide for what those look like).
• No obvious trigger. Nothing changed. It just started, or has been there forever.
• Normal labs, normal scopes, normal celiac panel. IBS is a diagnosis of pattern, not exclusion, but the workup is normal by definition.

None of these are diagnostic on their own. Plenty of SIBO patients have stress-triggered flares. Plenty of IBS patients have morning-to-evening bloating. The point is that the balance of features tips the pretest probability, which is how gastroenterologists actually think about who to breath-test.

How Each One Is Actually Diagnosed

The diagnostic pathways look different in a way that matters.

IBS: pattern plus exclusion of red flags

IBS is diagnosed on symptoms. The Rome IV criteria require recurrent abdominal pain, on average at least one day per week for the last three months, with symptom onset at least six months prior. The pain has to be associated with two or more of: defecation, a change in stool frequency, or a change in stool form.

That's the positive part. The negative part is ruling out anything else that could explain the same picture: celiac disease, inflammatory bowel disease, colorectal cancer, microscopic colitis, exocrine pancreatic insufficiency, and yes - SIBO. In practice, most gastroenterologists run a basic panel (CBC, CRP, celiac serology, fecal calprotectin in some cases), consider colonoscopy if age or red flags warrant it, and reach the IBS diagnosis when the symptoms fit and everything else is negative. If any alarm feature is present - unintended weight loss, GI bleeding, iron deficiency anemia, family history of colorectal cancer, new symptoms after 50 - the workup goes wider before IBS gets stamped on the chart. Our colorectal cancer warning signs guide covers the alarm features in more detail.

The 2021 ACG Clinical Guideline on IBS makes the diagnostic approach explicit: positive symptom criteria plus a limited, targeted evaluation for organic disease is enough. Routine broad testing in a low-risk patient hurts more than it helps.

SIBO: a breath test, with caveats

SIBO diagnosis is a physical one - you're looking for evidence of bacteria doing something they shouldn't. The theoretical gold standard is a jejunal aspirate during endoscopy: sample fluid from the small intestine, culture it, count colony-forming units per milliliter. Almost nobody does this in real practice because it's invasive, contamination-prone, and misses bacteria that don't culture well.

What actually happens: hydrogen and methane breath testing. You drink a sugar solution (glucose or lactulose), then breathe into a tube at fixed intervals for 2-3 hours. Bacteria fermenting the sugar in your small intestine release hydrogen or methane that crosses into your bloodstream and gets exhaled. The North American Consensus on breath testing (Rezaie et al., 2017) sets the cutoffs:

• Hydrogen: a rise of at least 20 ppm from baseline by 90 minutes is positive for SIBO
• Methane: a level of at least 10 ppm at any point during the test defines intestinal methanogen overgrowth (IMO), the constipation-associated variant

Glucose is more specific (fewer false positives) but only captures overgrowth in the upper small intestine, since it's absorbed by the time it gets further down. Lactulose travels the whole length of the small bowel but produces more false positives. Neither test is perfect. The 2020 ACG Clinical Guideline on SIBO is blunt: breath test accuracy is limited, and results have to be interpreted alongside symptoms, risk factors, and treatment response - not as a stand-alone yes/no.

Some clinicians will do a therapeutic trial of rifaximin in a highly suspicious patient without a breath test, and use response as the diagnostic. That's pragmatic. It's also expensive without insurance approval, which usually requires the test first.

How Treatment Diverges

This is where getting the right diagnosis actually pays off.

SIBO: kill the overgrowth, then fix the cause

For hydrogen-dominant SIBO, the first-line treatment is rifaximin, typically 550 mg three times daily for 14 days. Rifaximin is a non-absorbed antibiotic - it stays in the gut and has minimal systemic effects, which is why it's tolerable enough to use in a symptomatic condition. A meta-analysis pooling 32 studies found an overall eradication rate of about 70% (Gatta and Scarpignato, 2017). The 2020 ACG guideline recommends it for symptomatic patients with a positive breath test.

Methane-positive overgrowth (IMO) responds less reliably to rifaximin alone. Adding neomycin - or in some protocols, metronidazole - improves eradication, because methane-producing archaea are less susceptible to rifaximin monotherapy.

Antibiotics don't fix why the overgrowth happened. Recurrence rates are meaningful - one commonly cited study put SIBO recurrence at 44% nine months after successful rifaximin treatment. So the second half of SIBO treatment is addressing the underlying cause: chronic PPI use, diabetic gastroparesis, adhesions from prior surgery, opioid-induced motility slowing, hypothyroidism. Prokinetics (prucalopride, low-dose naltrexone, or in some patients low-dose erythromycin) are sometimes added to keep the migrating motor complex active between meals.

IBS: the multi-modal grind

IBS doesn't have a target to eradicate, so treatment is a stack of interventions matched to the subtype and severity. The 2021 ACG guideline is a fair summary of what actually gets recommended:

• Low-FODMAP diet as a limited trial. FODMAPs are fermentable carbs that feed gas-producing bacteria and pull water into the gut. A structured elimination-and-reintroduction protocol reduces symptoms in a majority of IBS patients. Not a long-term restriction - we walked through the mechanics in our low FODMAP diet guide.
• Soluble fiber (psyllium in particular) helps global IBS symptoms in both diarrhea- and constipation-predominant patients. Insoluble fiber like bran tends to make bloating worse.
• Rifaximin for IBS-D specifically. Interestingly, the same antibiotic used for SIBO is FDA-approved for IBS with diarrhea, which is part of why the two conditions are so tangled - the treatment for one is a documented treatment for a subset of the other.
• Chloride channel activators (lubiprostone) and guanylate cyclase activators (linaclotide, plecanatide) for IBS-C.
• Gut-directed psychotherapy - cognitive behavioral therapy or gut-directed hypnotherapy - for overall symptom relief. Strong evidence, chronically underused. The gut-brain axis is not metaphorical here; targeting it therapeutically produces measurable improvement.
• Antispasmodics and low-dose tricyclic antidepressants for pain-predominant patients, working as neuromodulators rather than antidepressants at those doses.
• Peppermint oil - actually recommended in the ACG guideline, with real trial data behind it.

Probiotics get asked about constantly. The AGA doesn't recommend them for IBS outside a research setting; individual strains have signal but the evidence isn't strong enough for a category endorsement. We got into what the data actually shows in our probiotics benefits writeup.

What happens when SIBO and IBS are both present

Treating the SIBO often doesn't fully resolve the IBS. This is the frustrating part. A patient with confirmed SIBO on top of underlying IBS can knock down bloating and gas with rifaximin, only to have the visceral hypersensitivity, dysmotility, and stress-triggered flares of IBS come back into focus once the overgrowth is gone. That doesn't mean the antibiotics failed. It means there were two things wrong, and only one has been fixed.

The reverse also happens: someone treated for years as IBS gets a positive breath test, a course of rifaximin, and 60% of their symptoms disappear. What looked like refractory IBS was mostly SIBO all along, with a smaller functional layer underneath.

When to Push for a SIBO Workup

If you carry an IBS diagnosis and it's been well-managed for years, you probably don't need to chase this. If any of the following applies, a breath test conversation with a gastroenterologist is worth having:

• Your IBS treatment isn't working. Low-FODMAP, fiber, and standard IBS drugs have made little dent in months of trying.
• Your symptoms started or worsened after a specific event. Abdominal surgery, a bad case of gastroenteritis, long-term PPI use, starting an opioid, a new diagnosis of diabetes or hypothyroidism.
• Your bloating is severe and clearly time-of-day dependent. Flat morning, distended by dinner, every day.
• You have unexplained B12 deficiency, iron deficiency, or steatorrhea. These aren't IBS features. They belong to a malabsorption picture.
• You improved unexpectedly after taking an antibiotic for something else. Amoxicillin for a sinus infection, doxycycline for acne. A history of transient GI improvement on antibiotics is suggestive.
• You have a condition on the SIBO risk list. Prior bowel surgery, scleroderma, diabetes with autonomic involvement, chronic pancreatitis, cirrhosis, HIV, common variable immunodeficiency, chronic opioid therapy.

The ACG SIBO guideline supports breath testing in symptomatic patients with any of these risk factors, and specifically in IBS-D patients who haven't responded to first-line therapy. It's a reasonable ask, not an aggressive one.

The Tracking Argument

Whichever condition you're working through, symptoms in your head are worse data than symptoms in an app. Both diagnoses lean on pattern recognition - stool form and frequency mapped against meals, timing, stress, medications, menstrual cycle - and both require a decent record to work through effectively.

For IBS specifically, the Rome IV criteria are inherently about counting: how many days per week, over how many months, what proportion of your bowel movements fell into which Bristol type. Trying to reconstruct that at a gastroenterology visit from memory is how patients get misclassified. For SIBO, response to treatment is often the confirming step; a two-week symptom log before rifaximin and a two-week log after is the cleanest way to tell whether the antibiotic did anything. Tracking what triggers symptoms - see our IBS food triggers writeup for common ones - is also the fastest way to isolate the meals or medications that keep flares coming back.

You don't need anything fancy. You need to log Bristol type, frequency, time relative to meals, and severity of bloating and pain, consistently enough to see the shape of what's happening. That's the thing your gastroenterologist can actually work from - and the thing that separates a real diagnostic pattern from a memory of the last bad week.